Age-related macular degeneration — AMD — is the leading cause of irreversible central vision loss in adults over 50 in the developed world. The standard tools the eye-care community uses to catch it early are good: a dilated fundus examination lets a clinician see drusen and pigment changes directly, optical coherence tomography (OCT) images the layers of the macula and is the workhorse for staging the disease, and the Amsler grid — the little square of straight lines patients tape to the fridge — is designed to catch the visual symptom that announces the wet, fast-moving form.
But there is a part of vision those tools don't directly probe, and that often slips before standard visual acuity does — the part that reads faces, road signs at dusk, low-contrast newsprint, and lane lines on wet asphalt: contrast sensitivity. In the AMD literature, contrast sensitivity has been documented as one of the earliest functional signals — sometimes measurable before standard acuity falls, and often more closely tied to how patients actually feel they are seeing.
The rest of this post is about why that signal exists in AMD, what the peer-reviewed work shows, and how a free, calibrated contrast sensitivity test you take at home fits alongside — never instead of — a dilated eye exam and OCT.
If you are over 50, especially if AMD runs in your family or you smoke or have smoked, please keep your annual eye exam on the calendar. A contrast sensitivity number is useful to bring into that conversation — not a substitute for it.
What AMD does to vision
The macula is the central few millimetres of the retina — the small, cone-dense region responsible for fine detail at the centre of your gaze. The rest of the retina, the periphery, is dominated by rods and handles motion, low-light, and the broad world around the point you are looking at. AMD is, fundamentally, a disease of the macula and the tissues that support it: the photoreceptors themselves, the retinal pigment epithelium (RPE) that nourishes them, and the Bruch's membrane beneath. When these layers begin to age abnormally, the result is a slow, often quiet erosion of central detail vision.
Clinicians describe AMD in two broad forms.
Dry (non-neovascular) AMD is the more common form, accounting for the large majority of cases. Its hallmarks are drusen — yellow-white deposits between the RPE and Bruch's membrane — and pigment changes in the RPE. Early and intermediate stages are typically slow and often symptom-free for years. The advanced dry form, geographic atrophy (GA), is a patch of dead RPE and overlying photoreceptors that enlarges over months and years and can spare the very centre of fixation for a surprisingly long time even when contrast and reading performance are already meaningfully impaired (Sunness et al., 1997).
Wet (neovascular) AMD is the less common but faster-moving form, in which abnormal new blood vessels grow under the macula, leak fluid and blood, and can cause irreversible central vision loss over days to weeks if not treated quickly. The symptomatic flag for wet AMD is metamorphopsia — straight lines look wavy or bent — which is exactly what the Amsler grid is designed to catch. Wet AMD is treatable when caught early; the window is short, which is why prompt evaluation matters.
Why does any of this affect contrast vision so early? Two reasons. First, the macula is where the cone photoreceptors that drive fine detail and edge vision are densely packed; subtle dysfunction in cones and the RPE that supports them shows up as reduced edge contrast before it shows up as loss of the smallest letters. Second, the underlying process — drusen, pigment change, sub-clinical RPE stress — can affect function before it produces visible structure large enough to image. The functional measurements — contrast sensitivity, low-luminance vision, dark adaptation — are the tools tuned to that early window.
What the literature shows on contrast sensitivity in AMD
The peer-reviewed evidence for reduced contrast sensitivity in AMD is robust at the group level and goes back decades.
Contrast sensitivity is reduced in early AMD before standard visual acuity falls. Kleiner, Enger, Alexander and Fine, in a 1988 paper in the Archives of Ophthalmology, compared 52 eyes with drusen — all with Snellen acuity of 20/20 — against 27 control eyes. The drusen group read fewer letters on every contrast-sensitivity chart tested, and the gap widened as contrast was reduced (Kleiner, Enger, Alexander & Fine, 1988). This is the classic pattern: standard acuity passes, contrast sensitivity does not. Midena and colleagues, in 1997, found a similar story with formal contrast sensitivity testing in early AMD eyes whose acuity was preserved (Midena, Degli Angeli, Blarzino, Valenti & Segato, 1997).
Geographic atrophy can decouple acuity from real-world vision. Sunness and colleagues, in a Wilmer Eye Institute natural-history study, documented that patients with GA and a relatively spared central island of fixation could maintain Snellen acuity of 20/50 or better while their contrast sensitivity, reading speed, and low-luminance acuity were already meaningfully impaired (Sunness et al., 1997). A later analysis found that the baseline low-luminance deficit — the gap between acuity at standard luminance and at low luminance — predicted subsequent acuity loss in GA patients more strongly than baseline acuity itself (Sunness et al., 2008). Low-luminance vision and contrast sensitivity are siblings; both reflect macular work in the regimes where the photoreceptor–RPE complex is most stressed.
The mid-to-high spatial frequency band carries much of the AMD signal. Healthy contrast sensitivity is an inverted-U curve across spatial frequency, peaking around 3–6 cycles per degree and falling toward about 18 cpd (background in our primer). In AMD, the mid-to-high band — driven heavily by the cone photoreceptor system clustered in the macula — is where reductions show up earliest in many patients. The early-glaucoma pattern is different: more often a low-to-mid band loss reflecting damage to the magnocellular retinal ganglion cells. The bands overlap; the shape across the whole curve is what carries diagnostic context.
A dark-adaptation story sits alongside the contrast one. Owsley and colleagues at the University of Alabama at Birmingham have shown that delayed rod-mediated dark adaptation — how long the rod photoreceptors take to recover sensitivity after a bright light — is a functional biomarker for incident AMD: older adults with healthy maculas but slow dark adaptation were several times more likely to develop early AMD within three years (Owsley et al., 2016). Dark adaptation is a different measurement from contrast sensitivity, but it belongs to the same broader picture: functional measurements catch macular trouble before structural ones do, on average.
Two honest caveats. First, "reduced on average at the group level" does not mean every patient with early AMD will show a contrast deficit, and not everyone with reduced contrast has AMD. The signal is real and replicated, not a stand-alone diagnostic. Second, almost all of the work above used calibrated clinical instruments — Pelli-Robson charts (Pelli, Robson & Wilkins, 1988), CSV-1000 instruments, lab-grade displays — with age-stratified norms from Mäntyjärvi and Laitinen (2001). An at-home test on your own screen is noisier; the underlying signal is the same, the measurement environment is not.
The Amsler grid and contrast sensitivity together
These two home tools answer different questions, and they complement each other rather than overlap.
The Amsler grid is a small square of fine straight lines with a central dot. You hold it at reading distance, cover one eye, look at the dot, and check whether the lines look straight or whether they bend, wave, or have a missing patch. It is designed to detect metamorphopsia and central scotoma — the visual symptoms that flag wet AMD or active geographic change. It is a yes/no, one-eye-at-a-time test, sensitive to sudden change. It is exactly the right tool for the question "is something happening right now that needs an urgent call?"
A contrast sensitivity test is a quantitative measurement of a different ability: how much contrast your visual system needs to see patterns of various sizes. It does not detect distortion. It does produce a number — and a curve across spatial frequencies — that you can compare against age-matched norms and against your own previous result on the same setup. It is the right tool for the question "is the part of vision that AMD tends to affect earliest performing below typical for my age, or trending down over time?"
You can — and if you are in a higher-risk group, you should — use both. They probe different things. Together they cover both the slow, drifting signal (contrast) and the fast, alarming one (distortion).
What an online CSF test can do for you with AMD risk
The honest framing is the same as for any other condition we have written about: a screening signal, a tracking tool, and a conversation-starter — never a diagnosis. What it can usefully do:
Give you a baseline. A single number, taken on the same device in the same lighting, that you can repeat. If you are 55 with a family history of AMD and your eye exams have been clean so far, a baseline contrast sensitivity result while your visual system is at its best is genuinely useful. The future trend is only legible against a present anchor.
Surface an earlier signal than acuity. Acuity is a coarse measure of the macula's best corner. Contrast sensitivity is sensitive to changes that have not yet pushed acuity off the chart. A drift downward on monthly retests is the kind of trend worth bringing to an ophthalmologist's attention sooner rather than later.
Bring trend data to the clinic. A six-month run of monthly contrast sensitivity numbers, on the same device, is a real artifact you can put in front of your eye doctor — a more textured input than "I think my vision is worse."
What it does not do is replace the dilated fundus examination and OCT that are the actual tools for detecting and staging AMD. OCT is the modern workhorse — it visualises drusen, pigment-epithelium changes, geographic atrophy boundaries, and intraretinal or subretinal fluid with millimetre-scale detail. Fluorescein angiography is reserved for cases where wet AMD is suspected and the vascular pattern needs to be mapped. No at-home test reaches that level. Nothing we make is meant to.
The longer background on what a contrast sensitivity test actually measures lives in our primer; the calibration and adaptive-procedure details for the version we built live on the methodology page.
What it cannot tell you
Note. A contrast sensitivity test is a screening signal of overall visual function. It does not diagnose AMD — or any other condition — and it cannot replace an ophthalmologic exam.
A normal contrast sensitivity result does not rule out AMD. Early AMD can be present with normal contrast sensitivity, particularly when drusen are small or peripheral to fixation. A clean result is reassuring; it is not exonerating.
A reduced contrast sensitivity result does not mean you have AMD. The list of other things that lower contrast sensitivity is long and includes things more common than AMD: uncorrected refractive error (the single most common cause — make sure your prescription is current), cataract, glaucoma, dry eye, diabetic retinopathy, MS, post-concussion vision change, normal aging, fatigue, medications, low room lighting, and screen-and-setup issues. Many of these are more common than AMD in any given age group.
A contrast sensitivity test cannot distinguish dry AMD from wet AMD. The two are clinically different — wet AMD is faster-moving, time-sensitive, and treated very differently — and they require imaging (OCT, and sometimes fluorescein angiography) to tell apart. If you are noticing sudden vision change, do not wait for a retest.
The test cannot stage AMD, cannot map drusen, cannot detect intraretinal fluid, and cannot replace the dilated fundus exam, OCT, or fluorescein angiography. Those are clinical tools; this is a functional measurement that sits alongside them.
Practical next steps
A reasonable schedule, by group:
If you are over 50 — keep an annual comprehensive eye exam on your calendar. If your provider doesn't routinely image the macula with OCT, ask whether one is warranted given your age and risk profile.
If you have a family history of AMD, smoke or have smoked, or have light-coloured irises — those are among the most consistent risk associations in the AMD literature. A baseline contrast sensitivity result now is worth taking. Mention the family history specifically at your next eye appointment so the macula gets the attention it deserves.
If you have been told you have drusen, intermediate AMD, or any other early macular finding — your eye-care provider will likely move you to a more frequent follow-up schedule (often every six months) and may refer you to a retinal specialist. The Amsler grid is typically recommended daily, one eye at a time, in this group, because catching a sudden change is the whole point of the at-home check at that stage. A monthly contrast sensitivity number is a reasonable complement — slow signal, daily check.
If you don't yet have an AMD diagnosis but are using contrast sensitivity as a baseline — monthly retests on the same device are plenty. Weekly Amsler grid is fine as a habit. Note any sudden change in either test.
Sudden change deserves an urgent call. Specifically: lines on the Amsler grid that newly look wavy or distorted; a fresh blurred or missing patch in central vision; an abrupt drop in your contrast sensitivity number alongside a subjective change. Wet AMD progresses in days to weeks; it is treatable, but the window is short. Do not wait for your annual appointment if something has changed acutely. Call your eye-care provider. If you are already in care with a retinal specialist, follow their guidance.
Take the test
Take the test now. Set a baseline. Retake it every month on the same device in the same lighting. Save the results.
A baseline number, retested; a daily or weekly Amsler grid; your annual dilated exam with an OCT when indicated. None of those pieces stands in for any of the others — each catches something the others can miss. The contrast sensitivity number is the one you can take in three minutes, today, at no cost. The rest is what your eye-care provider does best.
References
- Kleiner, R. C., Enger, C., Alexander, M. F., & Fine, S. L. (1988). Contrast sensitivity in age-related macular degeneration. Archives of Ophthalmology, 106(1), 55–57. Comparison of 52 eyes with drusen (all Snellen 20/20) against 27 control eyes; the drusen group read fewer letters on every contrast chart tested, with the gap widening as contrast fell — the classic "acuity passes, contrast does not" pattern in early AMD.
- Midena, E., Degli Angeli, C., Blarzino, M. C., Valenti, M., & Segato, T. (1997). Macular function impairment in eyes with early age-related macular degeneration. Investigative Ophthalmology & Visual Science, 38(2), 469–477. Documented contrast sensitivity and other macular function deficits in early AMD eyes with preserved visual acuity.
- Sunness, J. S., Rubin, G. S., Applegate, C. A., Bressler, N. M., Marsh, M. J., Hawkins, B. S., & Haselwood, D. (1997). Visual function abnormalities and prognosis in eyes with age-related geographic atrophy of the macula and good visual acuity. Ophthalmology, 104(10), 1677–1691. Documented reductions in contrast sensitivity, reading speed, and low-luminance acuity in geographic atrophy eyes whose central visual acuity was relatively spared.
- Sunness, J. S., Rubin, G. S., Broman, A., Applegate, C. A., Bressler, N. M., & Hawkins, B. S. (2008). Low luminance visual dysfunction as a predictor of subsequent visual acuity loss from geographic atrophy in age-related macular degeneration. Ophthalmology, 115(9), 1480–1488. The baseline low-luminance deficit predicted subsequent visual acuity loss in GA patients more strongly than baseline acuity itself — a key paper for the "functional measures lead structural change" picture.
- Owsley, C., McGwin, G., Jr., Clark, M. E., Jackson, G. R., Callahan, M. A., Kline, L. B., Witherspoon, C. D., & Curcio, C. A. (2016). Delayed rod-mediated dark adaptation is a functional biomarker for incident early age-related macular degeneration. Ophthalmology, 123(2), 344–351. Older adults with healthy maculas at baseline but delayed rod-mediated dark adaptation were several times more likely to develop early AMD within three years — supporting the broader picture that functional measurements catch macular trouble before structural ones.
- Pelli, D. G., Robson, J. G., & Wilkins, A. J. (1988). The design of a new letter chart for measuring contrast sensitivity. Clinical Vision Sciences, 2, 187–199. The Pelli-Robson chart paper — methodology anchor for clinical contrast sensitivity measurement.
- Mäntyjärvi, M., & Laitinen, T. (2001). Normal values for the Pelli-Robson contrast sensitivity test. Journal of Cataract and Refractive Surgery, 27(2), 261–266. Age-stratified normative Pelli-Robson values used as reference in clinical practice.